Robot semilla biodegradable
En este Short hablamos de un nuevo tipo de robot. …
Uncategorized
Nefecon Included in the Reimbursement Drug List of “Beijing Puhui Health Insurance Program” as a First-in-Disease Therapy for IgA Nephropathy
An imported version of Nefecon delayed release capsule has been added to the 2023 New Reimbursement Drug List of Specialized Medicines of the “Beijing Puhui Health Insurance Program.” Nefecon is a first-in-disease treatment for adults with primary immunoglobulin A nephropathy.
Mirion Technologies Announces Pricing of Public Offering by Selling Stockholders
Mirion Technologies, Inc. announced the pricing of an underwritten public offering of 7,000,000 shares of Mirion’s Class A common stock by certain selling stockholders at a price to the public of $7.65 per share.
Mirion Technologies Announces Pricing of Public Offering by Selling Stockholders Read More »
IntraOp Announces First Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Carcinomas
IntraOp Medical Corporation announced the world’s first Phase II Electron FLASH Trial.
Walgreens Boots Alliance Sells Shares of AmerisourceBergen Corporation for $694 Million of Initial Proceeds
Walgreens Boots Alliance, Inc. announced that it has sold shares of AmerisourceBergen Corporation common stock pursuant to variable prepaid forward transactions executed in reliance on Rule 144 of the Securities Act of 1933, as amended, for current proceeds of approximately $644 million.
Willow Biosciences Reports First Quarter 2023 Results
Willow Biosciences Inc. has released its financial and operating results for the three months ended March 31, 2023, reporting significant progress to its operational platform and strong liquidity.
Willow Biosciences Reports First Quarter 2023 Results Read More »
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
Cellectis published an article in Frontiers Bioenginnering, demonstrating the efficacy of its TALEN® engineered FAP UCART-cells in cancer-associated fibroblast depletion, reduction of desmoplasia and tumor infiltration.
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023
Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2023.
Ciclo de entrevistas “Invisibles” | Dra. María Lila Sylvestre Begnis: “Elegí ser médica general para atender a los más desprotegidos”
Recibida en Rosario, iba a especializarse como cirujana, pero un viaje la marcó. Jubilada del sistema público, hoy atiende en Andacollo, Neuquén, donde vive hace más de 30 años. Recomienda a los jóvenes trasladarse a los lugares donde más los necesitan.
Babylon Health to be taken private under restructuring deal
Babylon will receive $34.5 million in interim funding as part of a deal with investment manager AlbaCore Capital Group and its affiliates.
Babylon Health to be taken private under restructuring deal Read More »